CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Two dose MenACWY vaccineWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (8)


Name (Synonyms) Correlation
drug549 ChAdox1 n-CoV-19 (Abs 260) vaccine low dose Wiki 1.00
drug2470 Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care. Wiki 1.00
drug544 ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boost Wiki 1.00
drug1467 MenACWY vaccine Wiki 1.00
drug548 ChAdOx1 nCoV-19 plus 5x10^10vp boost (qPCR) Wiki 1.00
drug545 ChAdOx1 nCoV-19 (qPCR) Wiki 1.00
drug2568 Two dose MenACWY vaccine 4-12 weeks Wiki 1.00
drug543 ChAdOx1 nCoV-19 (Abs 260) Wiki 1.00

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 A Phase 2/3 Study to Determine the Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19

A phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in healthy UK volunteers.

NCT04400838 Coronavirus Biological: ChAdOx1 nCoV-19 (Abs 260) Biological: MenACWY vaccine Biological: ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boost Biological: Two dose MenACWY vaccine Biological: ChAdox1 n-CoV-19 (Abs 260) vaccine low dose Biological: ChAdOx1 nCoV-19 (qPCR) Biological: ChAdOx1 nCoV-19 plus 5x10^10vp boost (qPCR) Biological: Two dose MenACWY vaccine 4-12 weeks
MeSH:Coronavirus Infections

Primary Outcomes

Description: Number of virologically confirmed (PCR positive) symptomatic cases of COVID-19

Measure: Assess the efficacy of the candidate ChAdOx1 nCoV-19 against COVID-19 in adults aged 18 years and older.

Time: 6 months

Description: Occurrence of serious adverse events (SAEs) throughout the study duration.

Measure: Assess the safety of the candidate vaccine ChAdOx1 nCoV-19 in adults and children

Time: 6 months

Secondary Outcomes

Description: Occurrence of solicited local reactogenicity signs and symptoms for 7 days following vaccination

Measure: Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV-19: occurrence of solicited local reactogenicity signs and symptoms for 7 days following

Time: 7 days post vaccination

Description: Occurrence of solicited systemic reactogenicity signs and symptoms for 7 days following vaccination

Measure: Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV-19: occurrence of solicited systemic reactogenicity signs and symptoms for 7 days following

Time: 7 days post vaccination

Description: Occurrence of unsolicited adverse events (AEs) for 28 days following vaccination (except groups 4 & 6)

Measure: Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV-19: occurrence of unsolicited adverse events (AEs) for 28 days following vaccination

Time: 28 days post vaccination

Description: Frequency of participants with clinically significant changes from baseline for safety laboratory measures (haematology and biochemistry blood results; except groups 4 and 6)

Measure: Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV-19 through standard blood tests (full blood count, liver and kidney function tests)

Time: 6 months

Description: Occurrence of disease enhancement episodes

Measure: Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV-19 by measuring the number of disease enhancement episodes

Time: 6 months

Description: Number of hospital admissions associated with COVID-19

Measure: Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19: hospital admissions

Time: 6 months

Description: Number of intensive care unit (ICU) admissions associated with COVID-19

Measure: Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19

Time: 6 months

Description: Number of deaths associated with COVID-19

Measure: Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19: number of deaths

Time: 6 months

Description: Proportion of people who become seropositive for non-Spike SARS-CoV-2 antigens during the study

Measure: Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 by measuring seroconversion rates

Time: 6 months

Description: Quantify antibodies against SARS-CoV-2 spike protein (seroconversion rates)

Measure: Assess humoral immunogenicity of ChAdOx1 nCoV-19: antibody quantification

Time: 28 days post vaccination

Description: Proportion of seroconversion to antibodies against SARS-CoV-2 spike protein at Day 28 post-vaccination

Measure: Assess humoral immunogenicity of ChAdOx1 nCoV-19: seroconversion

Time: 28 days post vaccination

Description: Interferon-gamma (IFN-γ) enzyme-linked immunospot (ELISpot) responses to SARS-CoV-2 spike protein

Measure: Assess cellular and humoral immunogenicity of ChAdOx1 nCoV-19 through ELISpot assays (groups 1, 2 and 3 only)

Time: 6 months

Description: Occurrence of solicited local reactogenicity signs and symptoms for 7 days following booster vaccination

Measure: Assess the safety and immunogenicity of a booster dose of ChAdOx1 nCoV-19 in older adults aged 56 years or older (two-dose schedules for groups 1 and 2 only): local reactogenicity

Time: 7 days post vaccination

Description: Occurrence of solicited systemic reactogenicity signs and symptoms for 7 days following booster vaccination

Measure: Assess the safety and immunogenicity of a booster dose of ChAdOx1 nCoV-19 in older adults aged 56 years or older (two-dose schedules for groups 1 and 2 only): systemic reactogenicity

Time: 7 days post vaccination

Description: Occurrence of unsolicited adverse events (AEs) for 28 days following booster vaccination

Measure: Assess the safety and immunogenicity of a booster dose of ChAdOx1 nCoV-19 in older adults aged 56 years or older (two-dose schedules for groups 1 and 2 only)

Time: 28 days post vaccination

Description: Frequency of participants with clinically significant changes from baseline from pre-booster for safety laboratory measures (haematology and biochemistry blood results)

Measure: Assess the safety and immunogenicity of a booster dose of ChAdOx1 nCoV-19 in older adults aged 56 years or older (two-dose schedules for groups 1 and 2 only) through standard blood tests (full blood count, liver and kidney function tests)

Time: 6 months

Description: Antibodies against SARS-CoV-2 spike protein at Day 56 post-vaccination (seroconversion rates)

Measure: Assess the safety and immunogenicity of a booster dose of ChAdOx1 nCoV-19 in older adults aged 56 years or older (two-dose schedules for groups 1 and 2 only) via seroconversion

Time: 56 days post vaccination

Description: Proportion of seroconversion to antibodies against SARS-CoV-2 spike protein at Day 56 post-vaccination

Measure: Assess the safety and immunogenicity of a booster dose of ChAdOx1 nCoV-19 in older adults aged 56 years or older (two-dose schedules for groups 1 and 2 only)

Time: 56 days post vaccination

Other Outcomes

Description: Virus neutralising antibody (NAb) assays against live and/or pseudotype SARS-CoV-2 virus

Measure: Exploratory Immunology by virus neutralising antibody assays

Time: 6 months

Description: Cell analysis by flow cytometry assays

Measure: Exploratory Immunology by flow cytometry

Time: 6 months

Description: Functional antibody assays

Measure: Exploratory Immunology by functional antibody assays

Time: 6 months

Description: Anti-vector immunity induced by 1 or 2 doses of ChAdOx1 nCoV-19

Measure: Exploratory Immunology: anti-vector immunity

Time: 6 months

Description: Reported by weekly survey to collect information about cases amongst household contacts and friends, contact with the general public, infection control procedures

Measure: Measure exposure to COVID-19

Time: 6 months

Description: Number of PCR positive cases of COVID-19 infection

Measure: Exploratory efficacy against infection: assess efficacy of the candidate ChAdOx1 nCoV-19 against SARS-CoV-2 infection by PCR

Time: 6 months

Description: Measure of differences in viral loads between those with severe, mild, and asymptomatic PCR+ SARS-CoV-2 infections

Measure: Exploratory efficacy against infection: assess efficacy of the candidate ChAdOx1 nCoV-19 against SARS-CoV-2 infection

Time: 6 months

Description: Differences in safety, reactogenicity and immunogenicity profiles between Group 1 in COV001 and Group 5 in COV002 (proportion of Grade 3 solicited AEs, occurrence of fevers, seroconversion rates at D28, neutralising antibody titres and differences in T-cell responses at D14).

Measure: Compare safety, reactogenicity and immunogenicity between different manufacturing batches of ChAdOx1 nCoV-19 used in COV001 and COV002

Time: 6 months

Description: Differences in safety, reactogenicity and immunogenicity profiles between Groups 1, 2, and 5A compared with Groups, 7, 8, and 5B/C (proportion of Grade 3 solicited AEs, occurrence of fevers, seroconversion rates at D28, neutralising antibody titres and differences in T-cell responses at D14).

Measure: Compare safety, reactogenicity and immunogenicity between different methods for measuring doses (Abs260, Abs260 corrected for PS80, and qPCR) of ChAdOx1 nCoV-19

Time: 6 months

Description: Nasal mucosa IgA levels at D0 and D28 in a subset of individuals

Measure: Assess vaccine induced mucosal immunity: Nasal mucosa IgA levels at D0 and D28 in a subset of individuals

Time: 6 months

Description: Differences in viral shedding on stool at 7 days and beyond post SARS-CoV-2 positivity

Measure: Compare viral shedding on stool samples of SARS-CoV-2 PCR positive individuals

Time: 6 months

Description: Differences in antibody titres (ELISA and Neutralising antibodies) in participants who received 1 or 2 doses of ChAdOx1 nCoV-19 (groups 1, 2, 7 and 8)

Measure: Compare immunogenicity of ChAdOx1 nCoV-19 in participants receiving 1 or 2 doses in groups 1, 2, 7 and 8: differences in antibody titres

Time: 6 months

Description: Longevity of immune responses in participants who received 1 or 2 doses of ChAdOx1 nCoV-19

Measure: Compare immunogenicity of ChAdOx1 nCoV-19 in participants receiving 1 or 2 doses in groups 1, 2, 7 and 8: longevity of immune responses

Time: 6 months

Description: Differences reactogenicity profile, antibody titres and T-cell responses between groups 5d and 11 and their relationship with anti-vector neutralising antibody titres.

Measure: Describe the impact of previous vaccination with other ChAdOx1 vectored vaccines on safety and immune responses to ChAdOx1 nCoV-19

Time: 6 months


No related HPO nodes (Using clinical trials)